Skip to main content

Engineering human antibody derivatives, which specifically recognise and ablate new blood vessels, for the therapy of angiogenesis-related pathologies

Objective

Angiogenesis is a typical process, which underlies cancer, rheumatoid arthritis and the majority of blinding ocular disorders. The ability to selectively target and/or ablate new blood vessels will open diagnostic and therapeutic opportunities. Recently, our network has collaborated for the isolation of antibodies (Abs), which selectively recognise new-forming blood vessels. Two good-quality rankers of angiogenesis have been identified. The corresponding high-affinity phage Abs, efficiently target tumour neovasculature in vivo. We now propose to chemically modify anti-angiogenesis Abs and to test the biomedical potential of their conjugates. In particular, we will use radionuclides and fluorophores to investigate the potential of our labelled Abs for image diagnostics. We will also couple them to drugs, cytokines etc. and evaluate their therapeutic potential in suitable animal models. We will continue to search for novel markers of angiogenesis.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UNIVERSITÀ DEGLI STUDI DI SIENA
Address
Via Fiorentina 1
53100 Siena
Italy

Participants (5)

HELIOS KLINIKUM ERFURT GMBH
Germany
Address
Nordhaeuserstrasse 74
99089 Erfurt
INSTITUTO NAZIONALE PER LA RICERCA SUL CANCRO
Italy
Address
Largo Rosanna Benzi 10
16132 Genova
PHILOGEN SRL
Italy
Address
Centro Di Biotechnologie Avanzate, Largo Rosanna B
53100 Siena
SCHERING AG
Germany
Address
Muellerstrasse 178
13342 Berlin
SWISS FEDERAL INSTITUTE OF TECHNOLOGY ZUERICH
Switzerland
Address
Winterthurerstrasse 190
8057 Zurich